Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

NCT03246074 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Fostamatinib 100 mg bid and Paclitaxel
DRUG: Fostamatinib 150 mg bid and Paclitaxel
DRUG: Fostamatinib 200 mg bid and Paclitaxel

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]